THE WIRE · № 75956
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
01 THE MACHINE READ
WHY IT MATTERS.
Research on reduced dosing schedules for an approved TED drug could affect treatment protocols and drug demand, but no commercial data is given.
Early-stage TED dosing research, no market read-through yet
Peer review or label change on dosing
No commercial or trial-outcome data provided
FULL DISPATCH
LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 202026-10-12 11:05 UTC
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options2026-10-12 12:05 UTC
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks2026-10-12 12:09 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.